WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

*Shymaa Nema Hamed Alsaltani, Nawal Mehdi Firhan Alkhalidi and Samer Nema Yassen Alkemawy

ABSTRACT

Background: Nonalcoholic fatty liver disease (NAFLD) has emerged as one of the most prevalent chronic liver disorders worldwide, affecting approximately 25% of the global population. It encompasses a range of liver conditions, from simple steatosis, characterized by the accumulation of fat in the liver without significant inflammation, to nonalcoholic steatohepatitis (NASH). Aims of the study: To evaluate the efficacy of Omega 3 PUFA supplementation of daily 1 gram for 3 months in patients with non-alcoholic fatty liver disease. Method: A single-blind, randomized trial in Najaf, Iraq (March–Sept 2024) assessed Omega-3 PUFA (1g daily) versus placebo in 118 NAFLD patients over 12 weeks. Outcomes included liver function (ALT, AST, TG, FBS, cholesterol) and steatosis grading via ultrasound. Omega-3 supplementation showed potential benefits in improving biochemical and structural liver health. Results: The study found significant improvements in the Om3TP group after Omega-3 supplementation. BMI, waist circumference, triglycerides, ALT, AST, and ultrasound measurements significantly decreased (p<0.05), while HDL increased and fasting blood sugar reduced. No significant changes were observed in total cholesterol or LDL levels. The intervention effectively improved key health markers in NAFLD patients. Conclusion: The study found that omega-3 PUFA supplementation reduces triglycerides, liver enzymes (ALT and AST), and hepatic fat buildup in MASLD patients. It also lowers fasting blood sugar and raises BMI and HDL cholesterol. Total cholesterol, LDL, and waist circumference did not improve.

[Full Text Article] [Download Certificate]